| 标题： | 晚期肝细胞癌免疫靶向联合转化序贯外科治疗中国专家共识（2024版） |
| title： | Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma（2024 edition） |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 各级医疗机构中从事肝细胞癌诊治相关工作的临床医师、护理人员、技术人员及相关教学、科研工作等人员 |
| Guide users： | Healthcare workers involved in the diagnosis and treatment of hepatocellular carcinoma, including clinical physicians, nursing staff, technical personnel, and individuals engaged in teaching and research. |
| 证据分级方法： | 共识采用《牛津循证医学中心分级2011版》进行证据分级（证据等级：1~5），推荐意见分为：强推荐（推荐A）、中等程度推荐（推荐B）和弱推荐（推荐C） |
| Evidence grading method： | Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence |
| 制定单位： | 中华预防医学会肝胆胰疾病预防与控制专业委员会，中国抗癌协会肝癌专业委员会，北京医学会外科学分会肝脏学组 |
| Formulating unit： | Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, Liver Study Group of Surgery Committee of Beijing Medical Association |
| 注册时间： | 2024-09-04 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN846 |
| Registration number： | |
| 指南制订的目的： | 多达半数的肝细胞癌初诊时即为晚期，而晚期肝细胞癌缺乏有效的根治性治疗措施，预后较差。近年来，免疫检查点抑制剂联合抗血管生成靶向药物治疗晚期肝细胞癌已显示出较高的有效率，显著延长了患者的生存期，也为序贯外科根治性手术提供了可能。经转化治疗后序贯根治性肝切除或肝移植治疗，可使患者获得长期生存获益。为了提高肝癌总体人群的远期生存率，实现《“健康中国2030”规划纲要》癌症总体5年生存率提高15%的目标，中华预防医学会肝胆胰疾病预防与控制专业委员会、中国抗癌协会肝癌专业委员会、北京医学会外科学分会肝脏学组组织国内相关专业专家，就《基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识（2021版）》发布以来新的进展进行了深入的讨论，并就相关要点的修改、增补达成新的共识，以进一步指导临床实践，规范医疗行为，推动学科发展。 |
| Purpose of the guideline： | Up to half of hepatocellular carcinoma（HCC） cases are diagnosed at an advanced stage，for which effective treatment options are lacking，resulting in a poor prognosis. In recent years，the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has demonstrated high efficacy in treating advanced HCC，significantly extending patients' survival，and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy，patients can obtain long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the "Healthy China 2030" blueprint，the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association，Chinese Society of Liver Cancer，and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focus on the latest progress since the release of Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma（2021 Edition）and have reached new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice，standardize medical behavior，and promote the development of the discipline. |
